Minerva Neurosciences
NERV
92 hedge funds and large institutions have $230M invested in Minerva Neurosciences in 2019 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 30 increasing their positions, 22 reducing their positions, and 20 closing their positions.
431% more call options, than puts
Call options by funds: $1.03M | Put options by funds: $194K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
36% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 22
25% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 20
6% more funds holding
Funds holding: 87 → 92 (+5)
0.51% more ownership
Funds ownership: 9.86% → 10.37% (+0.51%)
4% less capital invested
Capital invested by funds: $239M → $230M (-$8.41M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.09M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.85M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$1.38M |
| 4 |
Millennium Management
New York
|
+$898K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$795K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
-$4.68M |
| 2 |
Handelsbanken Fonder
Stockholm,
Sweden
|
-$1.98M |
| 3 |
BlackRock
New York
|
-$1.62M |
| 4 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
-$1.47M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.06M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
D.E. Shaw & Co
New York
| – | -$126K | -2,037 | Closed |
|
|
MIM
102
MetLife Investment Management
Whippany,
New Jersey
| – | -$121K | -1,945 | Closed |
|
|
LI
103
Leap Investments
Chicago,
Illinois
| – | -$113K | -1,829 | Closed |
|
|
CS
104
Credit Suisse
Zurich,
Switzerland
| – | -$113K | -1,827 | Closed |
|
105
ProShare Advisors
Bethesda,
Maryland
| – | -$108K | -1,742 | Closed |
|
|
JG
106
Jefferies Group
New York
| – | -$97K | -1,559 | Closed |
|
|
MLICM
107
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$87.8K | -1,416 | Closed |
|
108
Victory Capital Management
San Antonio,
Texas
| – | -$47K | -764 | Closed |
|
109
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$35K | -558 | Closed |
|
|
QT
110
Quantamental Technologies
White Plains,
New York
| – | -$22K | -350 | Closed |
|
|
AL
111
AJO LP
Philadelphia,
Pennsylvania
| – | -$21K | -346 | Closed |
|
112
Daiwa Securities Group
Tokyo,
Japan
| – | -$2K | -27 | Closed |
|
NERV Hedge Fund Activity: Q4 2019 in Review
92 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q4 2019, worth a combined $230M — down 3.5% from $239M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new NERV positions and 20 closed out — a net gain of 5 holders — while 30 added to existing stakes and 22 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.09M. The largest seller was GMT Capital, exiting entirely with an estimated $4.68M sold.
- 92 institutional investors held Minerva Neurosciences (NERV) as of Q4 2019, up from 87 in Q3 2019.
- Funds reported $230M of Minerva Neurosciences stock for Q4 2019, down 3.5% quarter-over-quarter.
- 25 funds opened new Minerva Neurosciences positions in Q4 2019 and 20 closed out, a net change of +5 holders.
- The largest Minerva Neurosciences buyer in Q4 2019 was Armistice Capital, an estimated $3.09M added.
- The largest Minerva Neurosciences seller in Q4 2019 was GMT Capital, an estimated $4.68M sold.
Based on aggregated 13F filings for Q4 2019.